Pre-Made Interferon Beta Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-873

Pre-Made Interferon Beta Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Interferon beta is a cytokine in the interferon family used to treat multiple sclerosis (MS)

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-873-1mg 1mg 3090
GMP-Bios-INN-873-10mg 10mg Inquiry
GMP-Bios-INN-873-100mg 100mg Inquiry
GMP-Bios-INN-873-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Interferon Beta Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC
INN Name Interferon Beta
TargetIFNAR1
FormatRecombinant Protein
Derivation0
Species Reactivityhuman
CH1 IsotypeIFNB1 (interferon beta 1, IFNB) *a (C38) 22-187
VD LCIFNB1 (interferon beta 1, IFNB) *a (C38) 22-187
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesBiogen, Inc. (Cambridge MA USA) / Merck Serono International S.A. (Geneva Switzerland)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0